Selective COX-2 inhibitors do not increase gastrointestinal reactions after colorectal cancer surgery: a systematic review and meta-analysis

BACKGROUND: The effectiveness of selective COX-2 inhibitors in preventing colorectal cancer recurrence has been demonstrated, however it is unknown how safe and successful they will be over the long term.

As a result, we looked at the efficacy, safety, and consequences of adding COX-2 inhibitors to the treatment plan afterward.

METHODS: In patients with advanced colorectal cancer, we compared the efficacy of celecoxib at two different doses (200 mg twice day and 400 mg twice daily) with placebo.

To evaluate the impacts of post-treatment, several datasets from inception to June 2022 were searched.

Response rate, illness control rate, and 3-year survival were the main results.

And evaluated several safety outcomes, particularly those that were susceptible to adverse events.

RESULTS: The study comprised a total of 9 randomized controlled trials (3206 participants).

Celecoxib and rofecoxib doidn’t significantly improved the 1–3 year remission rate (OR, 1.57 [95% CI: 0.95–2.57]) and disease control rate (OR, 1.08 [95% CI: 0.99–1.17]).

Subgroup analysis of different doses showed that 400 mg of celecoxib significantly improved the response rate (OR, 2.82 [95%CI: 1.20–6.61]).

200 mg celecoxib was not significant (OR, 1.28 [95% CI: 0.66–2.49]).

Rofecoxib also did not fully improve disease response rates.

Celecoxib at any dose improved 3-year survival (OR, 1.21 [95% CI: 1.02–1.45]).

It is important to note that COX-2 inhibitors did not significantly enhance the likelihood of adverse events including gastrointestinal or cardiovascular side effects at any dose.

CONCLUSIONS: For patients with advanced colorectal cancer, a reasonable chemoprevention regimen can include celecoxib 400 mg twice daily.

SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02918-w.